Ionis (IONS) shares rise after-hours after FDA approval for Zanvastro
Ionis Pharmaceuticals shares edged up 1% after-hours Thursday after the FDA approved Zanvastro as the first treatment for Alexander disease, ahead of a stated deadline. Shares fell about 6% in regular trading after Ultragenyx reported a failed trial.
Ionis Pharmaceuticals (IONS) shares edged up 1% after-hours on Thursday after the U.S.
Food and Drug Administration (FDA) approved its drug Zanvastro as the first treatment for Alexander disease ahead of its own deadline.The stock had fallen about 6% in regular trading after Ultragenyx reported on…